- AustinPx has expanded its contract manufacturing capabilities.
- The company has added new spray drying and encapsulation capabilities and expanded its GMP manufacturing capacity.
- These additions are part of a larger strategy to better serve increasing client demand.
AustinPx, a contract development and manufacturing organisation (CDMO) specialising in analytical and formulation development services and cGMP manufacturing for small molecule drugs.
The company announced the expansion of its capabilities to meet industry demand for the company’s services and expertise. It has added new spray drying and encapsulation capabilities and has also expanded its GMP manufacturing capacity for high shear and fluid bed granulation.
“The investments are a key component of AustinPx’s larger strategy to expand our oral dose development and manufacturing capabilities to better serve our clients’ increasing demand,” said Justin Keen, PhD, senior vice president operations.
AustinPx has installed and validated a Dott. Bonapace INCAP capsule filler, a Freund-Vector VFC3 model fluid bed, and a Freund-Vector GMXB-Pilot model granulator. These additions demonstrate the company’s ongoing commitment to providing clients with the best possible service and support.
These expanded capabilities are now available for use and are the first of several strategic investments planned for the company in the immediate future.
Overview of outsourcing trends 
